

Author Relationships With Industry and Other Entities (Comprehensive)—2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (January 2016)

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Sana M. Al-Khatib <i>(Chair)</i>	Duke Clinical Research Institute; Duke University—Professor of Medicine	None	None	None	<ul style="list-style-type: none"> • AHRQ* • FDA* • NHLBI* • PCORI* • VA (DSMB) 	<ul style="list-style-type: none"> • HRS (Board of Trustees)† 	<ul style="list-style-type: none"> • Third Party, Implantable Cardioverter Defibrillator, 2017
William G. Stevenson <i>(Vice Chair)</i>	Vanderbilt University Medical Center—Professor OF Medicine; Brigham and Women’s Hospital—Director of Clinical Cardiac EP	<ul style="list-style-type: none"> • St. Jude Medical 	<ul style="list-style-type: none"> • Boston Scientific 	<ul style="list-style-type: none"> • Biosense Webster† 	None	<ul style="list-style-type: none"> • Circulation (Editor) * • NIH CABANA trial† • VANISH trial Steering Committee (Canadian Institutes for Health Research)† 	None
Michael J. Ackerman	Mayo Clinic—Professor of Medicine, Pediatrics, and Pharmacology; Long QT Syndrome/Genetic Heart Rhythm Clinic and the Mayo Clinic Windland Smith Rice Sudden Death Genomics Laboratory—Director	<ul style="list-style-type: none"> • Boston Scientific • Gilead Sciences • Invitae • Medtronic • Myokardia • St. Jude Medical • SADS* • Audentes Therapeutics 	None	<ul style="list-style-type: none"> • Transgenomic (Familion) * • Blue Ox Health Corporation† • AliveCor† • StemoniX† 	<ul style="list-style-type: none"> • NIH* 	<ul style="list-style-type: none"> • Transgenomic (Familion) * • Blue Ox Health Corporation† • AliveCor† • StemoniX† 	<ul style="list-style-type: none"> • Defendant, Long QT Related Death, 2016
William J. Bryant	Dominick Feld Hyde—Attorney at Law	None	None	None	None	<ul style="list-style-type: none"> • Alliance for a Healthier Generation† • AHA Corporate Relations Review Committee 	None

David J. Callans	University of Pennsylvania Health System—Professor of Medicine; Associate Director of EP	<ul style="list-style-type: none"> • Biosense Webster* • Biotronik • Boston Scientific* • Medtronic • St. Jude Medical 	None	None	<ul style="list-style-type: none"> • Biosense Webster (PI)† • Endosense (PI)† • St. Jude Medical (DSMB) • Hanssen (DSMB) • nContact (DSMB) • Impulse Dynamics (DSMB) 	None	None
Anne B. Curtis	University at Buffalo— SUNY Distinguished Professor; Charles and Mary Bauer Professor and Chair	<ul style="list-style-type: none"> • ACC • AHA • Daiichi-Sankyo* • Medtronic* • Sanofi Aventis • Novartis • Medscape* • St. Jude Medical* • WebMD 	None	None	<ul style="list-style-type: none"> • NHLBI (DSMB) • Medtronic 	None	None
Barbara J. Deal	Getz Professor of Cardiology Feinberg School of Medicine Northwestern University	None	None	None	None	None	None
Timm Dickfeld	University of Maryland— Professor of Medicine	<ul style="list-style-type: none"> • Biosense • Abbott/Topera* • St. Jude Medical • Siemens* 	None	None	<ul style="list-style-type: none"> • Biosense (PI)* • General Electric (PI)* • Impulse Dynamics (DSMB) • NIH 	<ul style="list-style-type: none"> • Impulse Dynamics† • Siemens* 	<ul style="list-style-type: none"> • Plaintiff, Perforation, 2015 • Plaintiff, SCD, 2015
Anne M. Gillis	University of Calgary— Professor of Medicine	<ul style="list-style-type: none"> • AHA 	None	None	<ul style="list-style-type: none"> • Medtronic* • Libin Cardiovascular institute 	None	<ul style="list-style-type: none"> • Defendant, Syncope and pacemaker, 2017

Christopher B. Granger	Duke Clinical Research Institute; Duke University—Professor of Medicine, Cardiac Care Unit	<ul style="list-style-type: none"> • Abbie • Armetheon • AstraZeneca* • Bayer* • Boehringer Ingelheim* • Boston Scientific • Bristol-Myers Squibb* • Daiichi-Sankyo* • Eli Lilly* • Gilead Sciences* • GlaxoSmithKline* • Hoffman-LaRoche* • Janssen Pharmaceuticals* • Medtronic* • Medscape • Merck • Novartis* • NIH* • Pfizer* • Sanofi-aventis* • Sirtex • Takeda Pharmaceutical* • The Medicines Company* • Verseon* 	None	None	<ul style="list-style-type: none"> • Armetheon* • AstraZeneca* • Bayer* • Boehringer Ingelheim* • Bristol-Myers Squibb* • Daiichi-Sankyo* • FDA* • GlaxoSmithKline* • Janssen Pharmaceuticals* • Medtronic* • Novartis* • Pfizer* • Sanofi-aventis* • Takeda Pharmaceutical* • The Medicines Company* 	<ul style="list-style-type: none"> • GE Healthcare* • Medtronic* • ZOLL Medical* • Spacelabs* • Phillips* 	None
Mark A. Hlatky	Stanford University School of Medicine—Professor of Health and Research Policy, and of Cardiovascular Medicine	<ul style="list-style-type: none"> • ACC* • Acumen* • Blue Cross/Blue Shield • Genetech 	None	None	<ul style="list-style-type: none"> • HeartFlow* • Sanofi-aventis‡ • George Institute • NHLBI (DSMB) 	None	None

Stephen C. Hammill	Mayo Clinic—Professor Emeritus of Medicine	None	None	None	None	None	None
José A. Joglar	UT Southwestern Medical Center—Professor of Internal Medicine; Clinical Cardiac EP—Fellowship Program Director	None	None	None	None	None	None
G. Neal Kay	University of Alabama at Birmingham—Professor Emeritus	None	None	None	None	None	None
Michael E. Field	University of Wisconsin School of Medicine and Public Health—Director, Clinical EP and Cardiac Arrhythmia Service, Associate Professor of Medicine	None	None	None	None	None	None

Gregg C. Fonarow	Ahmanson-UCLA Cardiomyopathy Center— Director; UCLA Division of Cardiology—Co-Chief	<ul style="list-style-type: none"> • Amgen • Janssen Pharmaceuticals • Medtronic • Novartis* • St. Jude Medical • ZS Pharma 	None	None	<ul style="list-style-type: none"> • Medtronic— IMPROVE-HF (Steering Committee)† • Medtronic* • NHLBI* • NIH/NIAID* • Novartis* 	<ul style="list-style-type: none"> • ACC/AHA Task Force on Data Standards† • ACC/AHA Task Force on Performance Measures (Chair)† • ACTION Registry Research and Publications Committee†† • AHA Workplace Health Steering Committee (Chair)† • AHA Consumer Health Quality Coordinating Committee† • AHA Manuscript Oversight Committee† • GWTG Steering Committee (PRT)† • JAMA Cardiology (Associate Editor) 	None
Daniel D. Matlock	University of Colorado School of Medicine— Associate Professor of Medicine	None	None	None	<ul style="list-style-type: none"> • AFAR* • NIH* • PCORI* 	<ul style="list-style-type: none"> • ACC • Circulation Cardiovascular Quality and Outcomes† • Medical Decision Making† • Journal of Palliative Medicine† 	None
Robert J. Myerburg	University of Miami Miller School of Medicine— Professor of Medicine and Physiology	None	None	None	<ul style="list-style-type: none"> • Miami Heart Research Foundation • VEST (DSMB) 	None	<ul style="list-style-type: none"> • Defendant, Various Medical Cases, 2015*

Richard L. Page	University of Wisconsin Hospital & Clinics—Chair, Department of Medicine	None	None	None	None	• FDA	None
-----------------	--	------	------	------	------	-------	------

This table represents all relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of $\geq 5\%$ of the voting stock or share of the business entity, or ownership of $\geq \$5,000$ of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to <http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy> for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees.

*Significant relationship.

†No financial benefit.

‡This disclosure was entered under the Clinical Trial Enroller category in the ACC's disclosure system. To appear in this category, the author acknowledges that there is no direct or institutional relationship with the trial sponsor as defined in the ACC/AHA Disclosure Policy for Writing Committees.

ACC indicates American College of Cardiology; ACTION, Acute Coronary Treatment and Intervention Outcomes Network; AHA, American Heart Association; AFAR, American Federation for Aging Research; CABANA; Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation; DSMB, data safety monitoring board; EP, Electrophysiology; GWTG, Get With The Guidelines; FDA, Food and Drug Administration; HRS, Heart Rhythm Society; IMPROVE-HF, Registry to Improve the use of Evidence-Based Heart Failure Therapies in the Outpatient Setting; JAMA, Journal of the American Medical Association; NIH, National Institutes of Health; NHLBI, National Heart, Lung, and Blood Institute; NIAID, National Institute of Allergy and Infectious Diseases; PACES, Pediatric and Congenital Electrophysiology Society; PCORI, Patient Centered Outcomes Research Institute; PI, principle investigator; PRT, pharmaceutical round table; SADS, Sudden Arrhythmia Death Syndromes Foundation; SMDM, Society for Medical Decision Making; UK, United Kingdom; and VANISH, Vasopressin Versus Noradrenaline as Initial Therapy in Septic Shock.